Evidence map›Paper›PMID 42894817›Full record

ArticleiScience2026

Genetic polymorphisms and early responses predict refractory hyperthyroidism during antithyroid drug therapy.

Xinpan Wang, Mengyi Gong, Jiayan Wang, Qiuyi Wang, Kuanfeng Xu, Qi Fu, Yun Cai, Zhixiao Wang, Xiaoyun Liu, Xinyu Xu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xinpan WangDepartment of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Mengyi GongDepartment of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Jiayan WangDepartment of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Qiuyi WangDepartment of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Kuanfeng XuDepartment of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Qi FuDepartment of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Yun CaiDepartment of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Zhixiao WangDepartment of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Xiaoyun LiuDepartment of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Xinyu XuDepartment of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Tao YangDepartment of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Xuqin ZhengDepartment of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antithyroid drugs (ATDs) are the first-line treatment for Graves' disease (GD), but variable outcomes require early risk stratification. We analyzed 578 adults, including 240 in a randomized trial of dose titration versus modified partial block-and-replace therapy and the remainder in a temporal observational cohort. Baseline characteristics, 3-month treatment indicators, and 13 GD-susceptibility single nucleotide polymorphisms (SNPs) were evaluated. An ATD-levothyroxine dose-correction method quantified thyroid function and autoantibody changes, informing clinical and SNP risk score-integrated models. The integrated model achieved areas under the curve (AUCs) of 0.841 in development and 0.805 in temporal validation, outperforming the clinical model (

Indexed as

antithyroid drugdose correctionearly therapeutic responsegenetic polymorphismsGraves’ diseaserefractorytreatment duration

Identifiers

PMID42894817
PMCPMC13676917

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.